Drug intelligence / Profile preview

Zinmax

Development stage: Phase 2
Lead developer: Nutrition21
Modality: Small Molecules
Administration: Oral

Overview

Zinmax is a premium-grade dietary supplement ingredient developed by Nutrition21, consisting of a highly bioavailable zinc picolinate formulation. By combining zinc with picolinic acid, Zinmax offers enhanced absorption compared to other common forms of zinc such as zinc citrate or zinc gluconate. As an essential mineral supplement, it supports a wide range of physiological functions, including immune system health, cardiovascular function, cellular metabolism, and hormonal balance. It is designed for use in various delivery formats such as tablets, capsules, gummies, and functional foods, and is marketed as a branded ingredient for the dietary supplement industry rather than as a standalone pharmaceutical drug.

Brand names: Zinmax
Other names: zinc picolinate

Beyond the preview

Go deeper on Zinmax.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zinmax.

Explore the full profile